Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03381183
Title IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute

hypopharynx cancer

laryngeal squamous cell carcinoma

paranasal sinus cancer

head and neck squamous cell carcinoma

oropharynx cancer

oral squamous cell carcinoma


Cyclophosphamide + Durvalumab + Tremelimumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
H. Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612 United States Details
University of Michigan Health System Ann Arbor Michigan 48019 United States Details
*Shaded cells indicate that there was no data available from for the field